Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients

C. Resteghini, S. Cavalieri, D. Galbiati, R. Granata, S. Alfieri, C. Bergamini, P. Bossi, L. Licitra, L. D. Locati

Research output: Contribution to journalReview articlepeer-review

Abstract

Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC. Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials. The toxicity burden associated to TKIs is not negligible. Drug reductions and interruptions are common, definitive drug withdrawals have also been reported as well as toxic deaths in more rare cases. In this context, the prevention of toxicities is mandatory to allow patients to stay on treatment as long as possible without dose and schedule modifications. Both physicians and patients should be educated to recognize drug-related toxicities in order to manage them in an early phase. Tools (e.g. toxicities summary booklet) for physicians and patients could be considered to improve the knowledge on side effects management. Guidelines, whenever available, should be followed.

Original languageEnglish
Pages (from-to)349-361
Number of pages13
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume31
Issue number3
DOIs
Publication statusPublished - Jun 1 2017

Keywords

  • gastrointestinal
  • hypertension
  • management
  • thyroid carcinoma
  • TKI
  • toxicity

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients'. Together they form a unique fingerprint.

Cite this